ROKIT Healthcare Inc.
Financials
Valuation Metrics
ROKIT Healthcare Inc.'s Market Cap is ₩5715B. At end of 2025 it was ₩1.0T. Ranked #416 of 2,436 in KR market (top 17%), #139 of 1,649 on KOSDAQ (top 8%), #48 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 571.46B KRW | KR#416/2,436 Sec#48/234 |
| Revenue | 30.61B KRW | KR#2,021/2,436 Sec#139/234 |
| Net Income | -4.33B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 116.95B KRW | KR#1,631/2,436 Sec#132/234 |
| Net Assets | 11.29B KRW | KR#2,355/2,436 Sec#226/234 |
| Employees | 86 | KR#1,741/2,436 Sec#137/234 |
| Value | ||
| P/B | 50.63x | KR#2,401/2,436 Sec#228/234 |
| P/S | 18.67x | KR#2,328/2,436 Sec#181/234 |
| FCF Yield | -3.04% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -38.35% | KR#2,223/2,436 Sec#185/234 |
| ROA | -3.70% | KR#1,820/2,436 Sec#134/234 |
| Op. Margin | -5.39% | KR#1,878/2,436 Sec#127/234 |
| Revenue Growth | 118.08% | KR#120/2,436 Sec#19/234 |
| Financial Health | ||
| Debt Ratio | 1036.15% | KR#2,354/2,436 Sec#229/234 |
| Total Debt | 25.58B KRW | KR#1,264/2,436 Sec#101/234 |
| FCF | -17.39B KRW | KR#1,864/2,436 Sec#176/234 |
| Cash | 68.20B KRW | KR#612/2,436 Sec#29/234 |
| Current Ratio | 1.01x | KR#1,802/2,436 Sec#180/234 |
| Performance | ||
| 1Y Return | 126.99% | KR#91/2,436 Sec#9/234 |
| 1M Return | -10.11% | KR#1,760/2,436 Sec#179/234 |
| From 52W High | -76.59% | KR#2,307/2,436 Sec#214/234 |
| 1Y MDD | -81.95% | KR#2,329/2,436 Sec#222/234 |
| Trading | ||
| Volume | 132,754 shares | KR#779/2,436 Sec#76/234 |
| Foreign Own. | 1.16% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -282 KRW | KR—/2,436 Sec—/234 |
| BPS | 683 KRW | KR#2,357/2,436 Sec#222/234 |
Company Info
Rokit Healthcare, established in 2012, leads the innovative regenerative medicine market. The company has commercialized AI ultra-precision patient-specific organ and skin regeneration platforms, built upon four core technologies including AI for medical lesion modeling and disposable regeneration kits. It provides an economical treatment method for chronic diseases, achieving 90% regeneration with a single procedure, and is expanding its application to cartilage and kidney regeneration platforms. Rokit Healthcare is headquartered in Geumcheon-gu, Seoul Metropolitan City.